Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary G-CSF prophylaxis duration in breast cancer chemotherapy
2007-005402-53Phase 4Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegfilgrastim in breast cancer, febrile neutropenia (FN), sponsored by Maastricht University Medical Center+. Started Jan 2008; status: terminated.
02
Drugs
pegfilgrastim
03
Conditions
breast cancerfebrile neutropenia (FN)
Beyond the preview
Go deeper on 2007-005402-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005402-53.